nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SIK1—mouth—pharynx cancer	0.0784	0.0919	CbGeAlD
Dabrafenib—SIK1—parotid gland—pharynx cancer	0.0546	0.064	CbGeAlD
Dabrafenib—NEK11—lymph node—pharynx cancer	0.0535	0.0628	CbGeAlD
Dabrafenib—RAF1—neck—pharynx cancer	0.0533	0.0625	CbGeAlD
Dabrafenib—SIK1—saliva-secreting gland—pharynx cancer	0.0523	0.0613	CbGeAlD
Dabrafenib—RAF1—parotid gland—pharynx cancer	0.0434	0.0509	CbGeAlD
Dabrafenib—RAF1—saliva-secreting gland—pharynx cancer	0.0416	0.0488	CbGeAlD
Dabrafenib—RAF1—brainstem—pharynx cancer	0.0407	0.0478	CbGeAlD
Dabrafenib—LIMK1—lymph node—pharynx cancer	0.0383	0.0449	CbGeAlD
Dabrafenib—RAF1—epithelium—pharynx cancer	0.0363	0.0426	CbGeAlD
Dabrafenib—SIK1—lymphoid tissue—pharynx cancer	0.0351	0.0412	CbGeAlD
Dabrafenib—RAF1—trachea—pharynx cancer	0.0321	0.0376	CbGeAlD
Dabrafenib—SIK1—spinal cord—pharynx cancer	0.0318	0.0373	CbGeAlD
Dabrafenib—SIK1—head—pharynx cancer	0.0283	0.0332	CbGeAlD
Dabrafenib—RAF1—lymphoid tissue—pharynx cancer	0.0279	0.0328	CbGeAlD
Dabrafenib—RAF1—spinal cord—pharynx cancer	0.0253	0.0297	CbGeAlD
Dabrafenib—BRAF—lymph node—pharynx cancer	0.0237	0.0278	CbGeAlD
Dabrafenib—RAF1—head—pharynx cancer	0.0225	0.0264	CbGeAlD
Dabrafenib—SIK1—lymph node—pharynx cancer	0.0198	0.0232	CbGeAlD
Dabrafenib—ABCG2—parotid gland—pharynx cancer	0.018	0.0211	CbGeAlD
Dabrafenib—ABCG2—saliva-secreting gland—pharynx cancer	0.0172	0.0202	CbGeAlD
Dabrafenib—RAF1—lymph node—pharynx cancer	0.0158	0.0185	CbGeAlD
Dabrafenib—SLC22A8—head—pharynx cancer	0.0131	0.0154	CbGeAlD
Dabrafenib—ABCG2—spinal cord—pharynx cancer	0.0105	0.0123	CbGeAlD
Dabrafenib—ABCB1—epithelium—pharynx cancer	0.0074	0.00868	CbGeAlD
Dabrafenib—ABCB1—trachea—pharynx cancer	0.00654	0.00768	CbGeAlD
Dabrafenib—ABCG2—lymph node—pharynx cancer	0.00652	0.00765	CbGeAlD
Dabrafenib—ABCB1—lymphoid tissue—pharynx cancer	0.0057	0.00669	CbGeAlD
Dabrafenib—SIK1—LKB1 signaling events—TP53—pharynx cancer	0.00566	0.0384	CbGpPWpGaD
Dabrafenib—CYP3A4—Fatty Acid Omega Oxidation—ADH7—pharynx cancer	0.00562	0.0381	CbGpPWpGaD
Dabrafenib—LIMK1—RAC1 signaling pathway—CDH1—pharynx cancer	0.0054	0.0366	CbGpPWpGaD
Dabrafenib—ABCB1—spinal cord—pharynx cancer	0.00517	0.00606	CbGeAlD
Dabrafenib—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—pharynx cancer	0.00492	0.0334	CbGpPWpGaD
Dabrafenib—ABCB1—head—pharynx cancer	0.00459	0.00539	CbGeAlD
Dabrafenib—LIMK1—CDC42 signaling events—CDH1—pharynx cancer	0.00439	0.0298	CbGpPWpGaD
Dabrafenib—BRAF—Bladder Cancer—CDH1—pharynx cancer	0.00421	0.0286	CbGpPWpGaD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—CCND1—pharynx cancer	0.0035	0.0238	CbGpPWpGaD
Dabrafenib—ABCB1—lymph node—pharynx cancer	0.00322	0.00377	CbGeAlD
Dabrafenib—BRAF—Bladder Cancer—CCND1—pharynx cancer	0.00314	0.0213	CbGpPWpGaD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—CD79A—pharynx cancer	0.00303	0.0206	CbGpPWpGaD
Dabrafenib—CYP2C8—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.00295	0.02	CbGpPWpGaD
Dabrafenib—RAF1—BCR signaling pathway—CD79A—pharynx cancer	0.00282	0.0191	CbGpPWpGaD
Dabrafenib—CYP2C8—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.00258	0.0175	CbGpPWpGaD
Dabrafenib—BRAF—Bladder Cancer—EGFR—pharynx cancer	0.00246	0.0167	CbGpPWpGaD
Dabrafenib—RAF1—GRB2 events in EGFR signaling—EGFR—pharynx cancer	0.00233	0.0158	CbGpPWpGaD
Dabrafenib—SIK1—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.00231	0.0157	CbGpPWpGaD
Dabrafenib—RAF1—SHC1 events in EGFR signaling—EGFR—pharynx cancer	0.00224	0.0152	CbGpPWpGaD
Dabrafenib—BRAF—CDC42 signaling events—CDH1—pharynx cancer	0.00219	0.0149	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—CD79A—pharynx cancer	0.0021	0.0142	CbGpPWpGaD
Dabrafenib—BRAF—Bladder Cancer—TP53—pharynx cancer	0.00207	0.014	CbGpPWpGaD
Dabrafenib—RAF1—Nanoparticle-mediated activation of receptor signaling—EGFR—pharynx cancer	0.00185	0.0125	CbGpPWpGaD
Dabrafenib—BRAF—Signaling events mediated by focal adhesion kinase—CCND1—pharynx cancer	0.00183	0.0124	CbGpPWpGaD
Dabrafenib—RAF1—GRB2 events in ERBB2 signaling—EGFR—pharynx cancer	0.00175	0.0119	CbGpPWpGaD
Dabrafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—EGFR—pharynx cancer	0.00175	0.0119	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—CNDP2—pharynx cancer	0.00173	0.0117	CbGpPWpGaD
Dabrafenib—RAF1—SHC1 events in ERBB2 signaling—EGFR—pharynx cancer	0.00166	0.0113	CbGpPWpGaD
Dabrafenib—SIK1—Circadian rythm related genes—TP53—pharynx cancer	0.00165	0.0112	CbGpPWpGaD
Dabrafenib—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—pharynx cancer	0.00158	0.0107	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—ADH7—pharynx cancer	0.00157	0.0106	CbGpPWpGaD
Dabrafenib—RAF1—CDC42 signaling events—CDH1—pharynx cancer	0.00152	0.0103	CbGpPWpGaD
Dabrafenib—RAF1—Internalization of ErbB1—EGFR—pharynx cancer	0.00145	0.00982	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—CCND1—pharynx cancer	0.00144	0.00978	CbGpPWpGaD
Dabrafenib—LIMK1—Regulation of Actin Cytoskeleton—EGFR—pharynx cancer	0.0014	0.00951	CbGpPWpGaD
Dabrafenib—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—pharynx cancer	0.00139	0.00941	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—ADH1B—pharynx cancer	0.00137	0.00931	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CDH1—pharynx cancer	0.00136	0.00926	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by focal adhesion kinase—CCND1—pharynx cancer	0.00126	0.00857	CbGpPWpGaD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—EGFR—pharynx cancer	0.00124	0.00843	CbGpPWpGaD
Dabrafenib—ABCG2—Fluoropyrimidine Activity—TP53—pharynx cancer	0.00119	0.00805	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—CDH1—pharynx cancer	0.00119	0.00805	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of retinoblastoma protein—CCND1—pharynx cancer	0.00119	0.00805	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—EGFR—pharynx cancer	0.00113	0.00767	CbGpPWpGaD
Dabrafenib—RAF1—Leptin signaling pathway—CCND1—pharynx cancer	0.00107	0.00726	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—EGFR—pharynx cancer	0.00103	0.007	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—CCND1—pharynx cancer	0.000997	0.00676	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—CCND1—pharynx cancer	0.000951	0.00645	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—TP53—pharynx cancer	0.000949	0.00644	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—EGFR—pharynx cancer	0.000931	0.00631	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—CNDP2—pharynx cancer	0.000929	0.0063	CbGpPWpGaD
Dabrafenib—BRAF—ErbB1 downstream signaling—EGFR—pharynx cancer	0.000928	0.00629	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—CCND1—pharynx cancer	0.000884	0.006	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD79A—pharynx cancer	0.000849	0.00576	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—ADH7—pharynx cancer	0.00084	0.0057	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—TP53—pharynx cancer	0.000791	0.00537	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—EGFR—pharynx cancer	0.000782	0.00531	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—TP53—pharynx cancer	0.000779	0.00528	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—CNDP2—pharynx cancer	0.000767	0.0052	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—EGFR—pharynx cancer	0.000753	0.00511	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—ADH1B—pharynx cancer	0.000737	0.005	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—CCND1—pharynx cancer	0.000736	0.00499	CbGpPWpGaD
Dabrafenib—BRAF—Disease—B4GALT5—pharynx cancer	0.000715	0.00485	CbGpPWpGaD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—EGFR—pharynx cancer	0.000701	0.00476	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—EGFR—pharynx cancer	0.000694	0.00471	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ADH7—pharynx cancer	0.000693	0.0047	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—CCND1—pharynx cancer	0.000681	0.00462	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—pharynx cancer	0.000657	0.00446	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—EGFR—pharynx cancer	0.000656	0.00445	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000656	0.00445	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—EGFR—pharynx cancer	0.000642	0.00435	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—EGFR—pharynx cancer	0.000637	0.00432	CbGpPWpGaD
Dabrafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—pharynx cancer	0.000626	0.00425	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000611	0.00414	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ADH1B—pharynx cancer	0.000608	0.00412	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—TP53—pharynx cancer	0.000582	0.00395	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—B4GALT5—pharynx cancer	0.000581	0.00394	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—EGFR—pharynx cancer	0.000577	0.00392	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000541	0.00367	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—pharynx cancer	0.000539	0.00366	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—EGFR—pharynx cancer	0.000538	0.00365	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—pharynx cancer	0.000535	0.00363	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CNDP2—pharynx cancer	0.000515	0.00349	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—CCND1—pharynx cancer	0.000509	0.00345	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000507	0.00344	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000507	0.00344	CbGpPWpGaD
Dabrafenib—RAF1—Disease—B4GALT5—pharynx cancer	0.000495	0.00336	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—pharynx cancer	0.000485	0.00329	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.000485	0.00329	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD79A—pharynx cancer	0.000484	0.00328	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—EGFR—pharynx cancer	0.000477	0.00324	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CNDP2—pharynx cancer	0.000477	0.00324	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—EGFR—pharynx cancer	0.000475	0.00322	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CDH1—pharynx cancer	0.000473	0.00321	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ADH7—pharynx cancer	0.000466	0.00316	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—EGFR—pharynx cancer	0.000456	0.00309	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—EGFR—pharynx cancer	0.000454	0.00308	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000454	0.00308	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—EGFR—pharynx cancer	0.000451	0.00306	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—EGFR—pharynx cancer	0.000449	0.00305	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.000449	0.00304	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—EGFR—pharynx cancer	0.000441	0.00299	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ADH7—pharynx cancer	0.000431	0.00293	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000423	0.00287	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000423	0.00287	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—EGFR—pharynx cancer	0.000423	0.00287	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—EGFR—pharynx cancer	0.000419	0.00284	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—EGFR—pharynx cancer	0.000416	0.00282	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000415	0.00282	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—EGFR—pharynx cancer	0.000413	0.0028	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ADH1B—pharynx cancer	0.000408	0.00277	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—EGFR—pharynx cancer	0.000399	0.00271	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000398	0.0027	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—B4GALT5—pharynx cancer	0.00039	0.00265	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ADH1B—pharynx cancer	0.000378	0.00257	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000374	0.00254	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—pharynx cancer	0.00037	0.00251	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.000362	0.00245	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—B4GALT5—pharynx cancer	0.000361	0.00245	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000334	0.00227	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CNDP2—pharynx cancer	0.000296	0.00201	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD79A—pharynx cancer	0.000294	0.00199	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—EGFR—pharynx cancer	0.000288	0.00195	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EGFR—pharynx cancer	0.000277	0.00188	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CDH1—pharynx cancer	0.00027	0.00183	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADH7—pharynx cancer	0.000268	0.00182	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—pharynx cancer	0.000261	0.00177	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CNDP2—pharynx cancer	0.000258	0.00175	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000239	0.00162	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADH1B—pharynx cancer	0.000235	0.00159	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADH7—pharynx cancer	0.000233	0.00158	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—B4GALT5—pharynx cancer	0.000224	0.00152	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADH1B—pharynx cancer	0.000204	0.00139	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—B4GALT5—pharynx cancer	0.000195	0.00133	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000188	0.00127	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—pharynx cancer	0.000186	0.00126	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—pharynx cancer	0.000164	0.00111	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDH1—pharynx cancer	0.000164	0.00111	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CNDP2—pharynx cancer	0.000159	0.00108	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—pharynx cancer	0.000158	0.00107	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000157	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—pharynx cancer	0.000153	0.00104	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADH7—pharynx cancer	0.000144	0.000975	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—pharynx cancer	0.000128	0.000866	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADH1B—pharynx cancer	0.000126	0.000855	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	0.00012	0.000817	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—pharynx cancer	0.000114	0.000773	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—pharynx cancer	0.000105	0.00071	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—pharynx cancer	9.57e-05	0.000649	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—pharynx cancer	8.94e-05	0.000606	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—pharynx cancer	8.83e-05	0.000599	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—pharynx cancer	7.88e-05	0.000535	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—pharynx cancer	7.51e-05	0.000509	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—pharynx cancer	6.18e-05	0.00042	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—pharynx cancer	5.19e-05	0.000352	CbGpPWpGaD
